DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ovarian Carcinosarcoma — screening already-approved drugs against its 33-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Carcinosarcoma maps to a 33-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian carcinosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 4 (FGFR4) — FGFR4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KH8 · 1.49 Å · ligand 1-[4-[(1~{R})-1-[3,5-bis(chloranyl)pyridin-4-yl]ethoxy]-5-cyano-pyridin-2-yl]-3-[6-methanoyl-5-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3-(2-morpholin-4-ylethoxy)pyridin-2-yl]urea (VVW). Experimental structure, not a prediction.
What the evidence adds up to
In a single-institution retrospective analysis of 31 patients with ovarian or primary peritoneal carcinosarcoma diagnosed between 1996 and 2017, median progression-free survival for all stages was 9.3 months and median overall survival was 19.7 months. Fifteen patients received carboplatin/paclitaxel as first-line therapy, seven received ifosfamide/paclitaxel, six received a different regimen, and three received no chemotherapy. Carboplatin/paclitaxel was associated with a statistically significant longer progression-free survival than ifosfamide/paclitaxel (17.8 vs. 8.0 months, p = 0.025). Overall survival was similar across all treatment groups, which the authors attribute to possible treatment crossover after progression. The study is limited by its small sample size and retrospective design.
A 2023 case report describes a patient with recurrent ovarian carcinosarcoma whose tumour had low HER2 expression (1+ by immunohistochemistry, negative by FISH). Treatment with trastuzumab deruxtecan produced a durable partial response. The authors suggest this might represent a possible treatment option for patients whose tumours express HER2, but no data from larger series or controlled trials are available.
A 2015 report of three cases reiterates that ovarian carcinosarcoma is rare, occurs mostly in elderly women, and carries an aggressive clinical course with poor prognosis. No new treatment data are provided.
What remains missing is any prospective randomised trial comparing first-line regimens specifically for ovarian carcinosarcoma, and any trial of trastuzumab deruxtecan in a defined HER2-expressing subgroup. The rarity of the tumour makes recruitment difficult, and no biomarker-stratified trial design has yet been funded or completed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMC Cancer · 2018 · 39 citations · open access
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature
AbstractBACKGROUND: The optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovarian carcinosarcoma treated at our institution with different first-line chemotherapy regimens. METHODS: This single-institution, retrospective analysis included all patients with ovarian or primary peritoneal carcinosarcoma diagnosed from September 1996 to July 2017. Kaplan Meier analysis with a log-rank Mantel-Cox test was used to compare PFS and OS between treatment groups, and a p-value of < 0.05 was considered statistically significant. RESULTS: Thirty-one patients met inclusion criteria: two patients were stage IC, 5 were stage II, 21 were stage III, and 3 were stage IV. The median PFS and OS for all stages was 9.3 and 19.7 months respectively. Fifteen patients (48%) received carboplatin/paclitaxel as first therapy, 7 (23%) received ifosfamide/paclitaxel, 6 (19%) received a different regimen, and 3 (10%) did not receive chemotherapy. Patients treated with carboplatin/paclitaxel had a statistically significant longer PFS when compared to those receiving ifosfamide/paclitaxel (17.8 vs. 8.0 months, p = 0.025). OS was similar between all comparisons. CONCLUSIONS: In summary, in our cohort of ovarian carcinosarcoma patients, median PFS is longer in patients treated with carboplatin/paclitaxel compared to ifosfamide/paclitaxel. Overall survival was similar for all treatment groups, potentially due to subsequent treatment crossover. Given the rarity and aggressive nature of this tumor, further study into optimal first-line chemotherapy is warranted.
Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
Abstract•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.
West Indian Medical Journal · 2015 · 0 citations · open access
Prımary Carcınosarcoma of the Ovary: A Report of Three Cases
AbstractWe aim to present three cases of carcinosarcoma of the ovary, a rare tumor associated with an aggressive clinical course and overall poor prognosis. Ovarian carcinosarcoma is a rare gynecologic malignancy that tends to develop in elderly women. These tumors are defined histologically by the presence of malignant epithelial and stromal elements. They are associated
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
